Asep Medical Confirms Ai For Better Biofilm Infections

By Author: Ben Gross
Total Articles: 433
Comment this article

In a recent presentation to the US Biophysical Society in Philadelphia, Dr. Bob Hancock, CEO of Asep Medical Holdings Inc., shared exciting news about the innovative use of artificial intelligence (AI) in developing new treatments for biofilm infections.

Biofilms, which are bacterial communities causing 65% of infections, are notoriously difficult to treat due to their resistance to antibiotics. Asep Medical's peptides have shown promising results in combating biofilms, potentially offering more effective treatments compared to current options. By utilizing neural network AI methods, the company has been able to predict and develop peptides with higher activity against biofilms, improving their ability to suppress inflammation - a key factor in biofilm infections. This breakthrough has opened up opportunities in various markets, such as oral health, wounds, and chronic rhinosinusitis, with Asep's peptides demonstrating excellent efficacy in model infections. The company's initial product will be an oral irrigant/rinse designed to prevent biofilm infections in the oral cavity, safeguarding against dental issues.

Furthermore, ...
... AI technology, specifically LASSO regression, is being leveraged in the development of the SepsetER blood-based gene expression test. This test, which is undergoing regulatory approval studies in the USA, was created at the University of British Columbia and aims to analyze immune responses to identify potential infections.

More Information : https://www.techdogs.com/tech-news/pr-newswire/asep-medical-confirms-the-use-of-ai-enables-improved-treatments-for-common-biofilm-infections-and-rapid-sepsis-diagnostics